Takeda raises first-half guidance
This article was originally published in Scrip
Takedahas raised its consolidated net profit forecast for the first half ended September 30th by ¥20.0 billion ($195.7 million) to ¥70.0 billion. The figure compares with ¥218.0 billion in the same period of last year and reflects the dissolution of the TAP joint venture in the US and costs associated with the acquisition of Millennium Pharmaceuticals. The Japanese firm raised its sales outlook by ¥45.0 billion to ¥805.0 billion (+14%), boosted by Millennium, stronger sales in Japan and exchange rate gains, while operating profit should come in ¥35.0 billion ahead of earlier guidance at ¥85.0 billion (-68%). The company will release an updated full-year forecast at the time of its first-half results on November 4th.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.